{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:20:50Z","timestamp":1790824850975,"version":"4.1.0"},"reference-count":80,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T00:00:00Z","timestamp":1651622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Aurinia Pharmaceuticals Inc"},{"name":"provided funding for the voclosporin clinical studies and support for medical writing to develop the publication"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2022,5,4]]},"DOI":"10.1080\/17512433.2022.2092470","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T15:23:19Z","timestamp":1656429799000},"page":"515-529","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":64,"title":["Voclosporin: a novel calcineurin inhibitor for the treatment of lupus nephritis"],"prefix":"10.1080","volume":"15","author":[{"given":"Teun","family":"van Gelder","sequence":"first","affiliation":[{"name":"Leiden University Medical Center","place":["Leiden, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0976-5478","authenticated-orcid":false,"given":"Edgar","family":"Lerma","sequence":"additional","affiliation":[{"name":"University of Illinois at Chicago College of Medicine\/Advocate Christ Medical Center","place":["Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kory","family":"Engelke","sequence":"additional","affiliation":[{"name":"Aurinia Pharmaceuticals Inc","place":["Victoria, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Huizinga","sequence":"additional","affiliation":[{"name":"Aurinia Pharmaceuticals Inc","place":["Victoria, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05780616"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev311"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21664"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39594"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa381"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0896860820934730"},{"issue":"1801","key":"e_1_3_6_9_1","first-page":"11","article-title":"Diagnosis and management of nephrotic syndrome","volume":"261","author":"McCloskey O","year":"2017","unstructured":"McCloskey O, Maxwell AP. Diagnosis and management of nephrotic syndrome. Practitioner. 2017;261(1801):11\u201315.","journal-title":"Practitioner"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.11.023"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.39026"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015"},{"issue":"4","key":"e_1_3_6_14_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"Clinical practice guideline for the management of glomerular diseases","volume":"100","author":"KDIGO","year":"2021","unstructured":"KDIGO. Clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s):S1\u2013S276.","journal-title":"Kidney Int"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab351"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00009-6"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37940"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00578-X"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.622225"},{"key":"e_1_3_6_22_1","unstructured":"Lupkynis voclosporin [prescribing information] 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/213716s000lbl.pdf."},{"key":"e_1_3_6_23_1","unstructured":"Benlysta B [prescribing information] 2017 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125370s062lbl.pdf."},{"key":"e_1_3_6_24_1","unstructured":"Benlysta belimumab [summary of product characteristics] 2016 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/benlysta-epar-product-information_en.pdf."},{"key":"e_1_3_6_25_1","unstructured":"US Food and Drug Administration. Voclosporin Approval Letter 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/213716Orig1s000Approv.pdf."},{"key":"e_1_3_6_26_1","volume-title":"Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis","author":"Furie R","unstructured":"Furie R, Aroca G, and Alvarez A, et al. Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis. Arthritis Rheumatol. 2020;72(suppl 10). [cited 2022 Jun, 27]. Available from: https:\/\/acrabstracts.org\/abstract\/two-year-results-from-a-randomized-controlled-study-of-obinutuzumab-for-proliferative-lupus-nephritis\/. abstract 0988."},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2005.00080.x"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04800908"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2019.08.006"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a035436"},{"key":"e_1_3_6_31_1","unstructured":"Prograf tacrolimus [prescribing information] 2012 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050709s031lbl.pdf."},{"key":"e_1_3_6_32_1","unstructured":"Gengraf cyclosporin. [prescribing information] 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/www.gengraf.com\/prescribinginformation."},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S255789"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007121272"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2010.08.036"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr484"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312448105"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1030"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S189156"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000640"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.08.025"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00757-6"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444910051905"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.166"},{"key":"e_1_3_6_45_1","unstructured":"US Food and Drug Administration. Multi-disciplinary review and evaluation NDA 213716 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/213716Orig1s000MultidisciplineR.pdf."},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12309"},{"issue":"1","key":"e_1_3_6_47_1","first-page":"173","article-title":"Cyclosporine metabolite profiles in the blood of liver transplant patients","volume":"20","author":"Wang CP","year":"1988","unstructured":"Wang CP, Burckart GJ, Venkataramanan R, et al. Cyclosporine metabolite profiles in the blood of liver transplant patients. Transplant Proc. 1988;20(1 Suppl 1):173\u2013175.","journal-title":"Transplant Proc"},{"key":"e_1_3_6_48_1","unstructured":"US National Library of Medicine PubChem 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/cyclosporin."},{"issue":"2","key":"e_1_3_6_49_1","first-page":"591","article-title":"Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients","volume":"20","author":"Wang CP","year":"1988","unstructured":"Wang CP, Burckart GJ, Ptachcinski RJ, et al. Cyclosporine metabolite concentrations in the blood of liver, heart, kidney, and bone marrow transplant patients. Transplant Proc. 1988;20(2 Suppl 2):591\u2013596.","journal-title":"Transplant Proc"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(01)01929-7"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V42168"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1857"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132724"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1967747"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.109718"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.114"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2004.tb00509.x"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(03)00033-0"},{"issue":"2020","key":"e_1_3_6_59_1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1681\/ASN.20203110S1594c","article-title":"Use of TDM does not add clinical value for voclosporin in patients with lupus nephritis [abstract PO 1918]","volume":"31","author":"van Gelder T","year":"2020","unstructured":"van Gelder T, Huizinga RB, Noukens J, et al. Use of TDM does not add clinical value for voclosporin in patients with lupus nephritis [abstract PO 1918]. J Am Soc Nephrol. 2020;31(Kidney Week 2020):594.","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199711270-00022"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(99)80044-7"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1212659"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.33549\/physiolres.933332"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199911270-00028"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.06.036"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab022"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10214832"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203311418269"},{"key":"e_1_3_6_69_1","unstructured":"Askanase A Randhawa S Lisk L et al. Efficacy of voclosporin across lupus nephritis biopsy classes: pooled data from the Aurora and AURA-LV trials. Presented at the virtual Nation Kidney Foundation 2021 Spring Clinical Meeting 2021 Apr 6\u201310. Poster 283 [cited 2022 Mar 15]. https:\/\/casehippo.com\/spa\/symposium\/national-kidney-foundation-2021-spring-clinical-meetings\/event\/gallery\/abstracts?abstractId=1878"},{"key":"e_1_3_6_70_1","unstructured":"US National Library of Medicine ClinicalTrials.gov [Internet] 2021 cited 2022 Mar 15]. Available from 2022 Mar 15: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03597464."},{"key":"e_1_3_6_71_1","volume-title":"Voclosporin for lupus nephritis: interim analysis of the Aurora 2 extension study [abstract 1425]","author":"Saxena A","year":"2021","unstructured":"Saxena A, Mela C, Coeshall A, editors. Voclosporin for lupus nephritis: interim analysis of the Aurora 2 extension study [abstract 1425]. American College of Rheumatology Convergence; 2021. cited 2022 Mar 15]. Available from 2022 Mar 15 https:\/\/acrabstracts.org\/abstract\/voclosporin-for-lupus-nephritis-interim-analysis-of-the-aurora-2-extension-study\/"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2008101028"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38037"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00261"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.5049\/EBP.2007.5.2.126"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.2018.1549193"},{"key":"e_1_3_6_77_1","volume-title":"European renal association-European dialysis and transplant association","author":"Tumlin JA","unstructured":"Tumlin JA, Rovin BH, and Rahman M, et al. Voclosporin therapy in active lupus nephritis: reduced hypertension and electrolyte complications with CNI treatment [abstract]. 2017th ed. Vol.32, European renal association-European dialysis and transplant association Madrid Spain: Nephrology Dialysis Transplantation; 2017.","edition":"2017"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa162"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2011.03763.x"},{"key":"e_1_3_6_80_1","unstructured":"Otsuka press release 2021. [cited 2022 Mar 15]. Available from: https:\/\/www.otsuka.co.jp\/en\/company\/newsreleases\/2021\/20210625_1.html."},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191008"},{"issue":"10","key":"e_1_3_6_82_1","first-page":"1495","article-title":"The effectiveness and value of belimumab and voclosporin for lupus nephritis","volume":"27","author":"Tice JA","year":"2021","unstructured":"Tice JA, Mandrik O, Thokala P, et al. The effectiveness and value of belimumab and voclosporin for lupus nephritis. J Manag Care Spec Pharm. 2021;27(10):1495\u20131499.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2022.2092470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:58:59Z","timestamp":1770897539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2022.2092470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,4]]}},"alternative-id":["10.1080\/17512433.2022.2092470"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2022.2092470","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}